.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The HORIZON randomized trial evaluated the Hydrus Microstent in patients with primary open-angle glaucoma undergoing cataract surgery. At five years, eyes receiving the Schlemm's canal microstent had a higher proportion of medication-free eyes with controlled intraocular pressure than eyes receiving cataract surgery alone. The Hydrus group also had a lower cumulative need for subsequent incisional glaucoma surgery, while long-term endothelial cell loss was not significantly different between groups. These findings provide meaningful support for a MIGS approach in selected patients with mild-to-moderate POAG and cataract. The important qualification is that MIGS is not equivalent to trabeculectomy for very advanced or very low-target-pressure disease. Instead, the value is greatest when modest additional pressure lowering and medication reduction are clinically meaningful. For HCPs, patient selection should include baseline IOP, disease stage, medication burden, angle anatomy and target pressure. The five-year data are particularly useful because they move beyond the short-term postoperative period and demonstrate that the benefit can persist. This fits AIOC's focus on MIGS and contemporary glaucoma surgery.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The HORIZON randomized trial evaluated the Hydrus Microstent in patients with primary open-angle glaucoma undergoing cataract surgery. At five years, eyes receiving the Schlemm's canal microstent had a higher proportion of medication-free eyes with controlled intraocular pressure than eyes receiving cataract surgery alone. The Hydrus group also had a lower cumulative need for subsequent incisional glaucoma surgery, while long-term endothelial cell loss was not significantly different between groups. These findings provide meaningful support for a MIGS approach in selected patients with mild-to-moderate POAG and cataract. The important qualification is that MIGS is not equivalent to trabeculectomy for very advanced or very low-target-pressure disease. Instead, the value is greatest when modest additional pressure lowering and medication reduction are clinically meaningful. For HCPs, patient selection should include baseline IOP, disease stage, medication burden, angle anatomy and target pressure. The five-year data are particularly useful because they move beyond the short-term postoperative period and demonstrate that the benefit can persist. This fits AIOC's focus on MIGS and contemporary glaucoma surgery.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
